Shareholder Alert: Robbins LLP Announces It Is Investigating the Officers and Directors of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Shareholders

Shareholder rights law firm Robbins LLP announces it is investigating whether certain officers and directors of Verrica Pharmaceuticals Inc. (NYSE: VRCA) violated federal securities laws. Verrica is a clinical stage medical dermatology company that develops and commercializes dermatological treatments.

If you suffered a loss as a result of Verrica's misconduct, click here.

Verrica Pharmaceuticals Inc. (VRCA) Announces Receipt of FDA Letter

On June 29, 2020, Verrica disclosed that on June 24, 2020, the Company had received a letter from the U.S. Food & Drug Administration ("FDA") as part of the FDA’s ongoing review of the Company’s New Drug Application (NDA) for VP-102, the Company's lead product candidate for the treatment of molluscum contagiosum. The letter stated that there were deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. Verrica then noted that the FDA requested information "related to a potential safety issue with the applicator that could arise if the instructions for use were not properly followed." On this news, Verrica's stock price fell 28% over the next two trading days to close at $10.16 per share on July 1, 2020.

Verrica Pharmaceuticals Inc. (VRCA) Shareholders Have Legal Options

Contact us to learn more:

Leo Kandinov

(800) 350-6003

[email protected]

Shareholder Information Form

Want to be notified if a class action on behalf of Verrica settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200706005612/en/